Start thinking “cure” in cancer, Janssen’s head of global oncology therapeutics advised pharma executives during a virtual meeting. (Fierce Pharma)
Patients with early-stage, HER2-negative, BRCA-mutant breast cancer should be offered a year of adjuvant olaparib (Lynparza) following neoadjuvant therapy and local treatment, according to a rapid guideline update from the American Society of Clinical Oncology.
“Give me one more hug.” When words fail during an oncologist’s last meeting with a dying patient. (JCO: Art of Oncology)
A phase I trial of the IDH1/2 inhibitor vorasidenib in recurrent non-enhancing glioma showed a favorable safety profile, an objective response rate of 18%, and a median progression-free survival of 3.1 years, Servier announced.
A survey by the American Academy of Dermatology showed that only a third of Americans are concerned about developing skin cancer, even though 70% may have one or more risk factors.
Results of a phase I/II trial of the RET inhibitor pralsetinib (Gavreto) showed response rates of 60% to 90% in RET fusion-positive non-small cell lung cancer and RET fusion-positive or RET-mutant thyroid cancer. (University of Texas MD Anderson Cancer Center)
Uncovering more clues to the association between high-fat diet and colon cancer. (Cell Reports, Arizona State University)
A personalized liquid biopsy showed potential for predicting outcomes with immunotherapy for bladder cancer. (Nature)
Legislation introduced in both houses of Congress would ban a class of potentially cancer-causing chemicals known as PFAS from a variety of widely used cosmetics. (CNN)
Does mortgage lending bias affect breast cancer survival? (Journal of Clinical Oncology)